Softwr

Research · head to head

Medidata Rave vs Remesh

Medidata Rave logo

Medidata Rave

Research

Electronic data capture for regulated clinical trials, sold only through a sales process

From
On request
Rated
-
Full reviewWebsite
Remesh logo

Remesh

Research

Live AI-moderated conversations with hundreds of participants at once, analysed in real time

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Medidata Rave no pricing is published at all, so a first time sponsor cannot budget a study without entering a sales process and usually cannot benchmark the quote against anything.; Remesh pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
  • They diverge on capability: Medidata Rave covers Case report form design, Remesh covers Live moderated sessions.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Medidata Rave and Remesh actually diverge.

Attributes where Medidata Rave and Remesh differ
AttributeMedidata RaveRemesh
PlatformsWebWeb, API

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Medidata Rave

  • Case report form design
  • Edit checks and queries
  • Part 11 audit trail
  • Rave Lite
  • Coding and safety
  • Platform integrations

Only in Remesh

  • Live moderated sessions
  • Collective dialogue
  • Flex asynchronous studies
  • Video research
  • Remy AI assistant
  • On-Demand Recruit
  • Real-time theme analysis
  • Practice sessions

What people use each for

The jobs each tool is most often brought in to do.

Medidata Rave

  • A sponsor running a registrational Phase III study where inspection readiness and a validated audit trail are non negotiablenot Remesh
  • A biotech that wants its CRO to run data management and benefits from the CRO already having Rave trained staff and templatesnot Remesh
  • A sponsor standardising forms across a programme so that a global library is reused rather than each study being built from scratchnot Remesh
  • A device or Phase IV study where Rave Lite gives the same compliance posture at a lower configuration burdennot Remesh

Remesh

  • A brand team that needs to test three positioning statements with 400 target customers and know by the end of the day which one lands and with whomnot Medidata Rave
  • An HR function running an employee listening session across several thousand staff where anonymity and volume both matternot Medidata Rave
  • A public affairs team needing rapid citizen consultation on a policy option with evidence of how widely each objection is heldnot Medidata Rave
  • An insights team that has to replace six focus groups with one session because fieldwork time has been cut and the decision cannot waitnot Medidata Rave

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Medidata Rave

  • No pricing is published at all, so a first time sponsor cannot budget a study without entering a sales process and usually cannot benchmark the quote against anything.
  • Cost is dominated by study build rather than licence, and every protocol amendment that changes a form triggers billable rework, so a study with unstable protocols costs far more than the initial quote implied.
  • Configuration requires trained specialists, so most sponsors cannot build a study in house and are dependent on Medidata professional services or a CRO, which lengthens startup.
  • The system assumes a professional clinical data management function; a small sponsor without data managers will not operate it directly and will pay a CRO to do so.
  • Deep use of the wider Medidata platform for randomisation, imaging and patient reported data creates commercial lock in, because moving EDC later means unpicking integrations that were bought as one bundle.

Remesh

  • Pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
  • The public review picture is inconsistent in a way worth investigating: a small number of positive buyer reviews on G2 sit alongside a poor Trustpilot rating driven mostly by participant complaints, so ask directly how participants are recruited and compensated before running a study on your own customers.
  • Funding has slowed sharply, from a 25 million USD round in 2021 to a 4.25 million USD round in late 2022, so procurement teams at large organisations should expect to run a vendor viability review.
  • The collective dialogue mechanic rewards views that many participants recognise and vote for, which systematically under-weights genuinely novel minority insight, so it is a poor fit for exploratory discovery work where the outlier is the point.
  • The discussion guide builder, especially spreadsheet import, is reported as unreliable, and because sessions are live with recruited participants a tooling failure during setup is expensive rather than merely annoying.

Pricing, plan by plan

Medidata Rave

On request
  • Medidata Rave EDC$undefined/year
    • Priced per study through a sales process
    • Study build and configuration charged separately from licence
    • Mid study amendments generally billable

Remesh

On request
  • Remesh$undefined/year
    • Live moderated sessions
    • Flex asynchronous studies
    • Video research

Which should you pick?

Choose Medidata Rave if

  • You need case report form design.
  • You also want edit checks and queries.
Medidata Rave review

Choose Remesh if

  • You need live moderated sessions.
  • You work on Web, API.
  • You also want collective dialogue.
Remesh review

Questions people ask

Is Medidata Rave or Remesh better?
Neither clearly leads. Medidata Rave starts at On request and Remesh at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Medidata Rave or Remesh?
Medidata Rave starts at On request and Remesh at On request.
Does Medidata Rave or Remesh run on more platforms?
Medidata Rave runs on Web. Remesh runs on Web, API.
What is Medidata Rave best used for?
Medidata Rave is most often used for a sponsor running a registrational phase iii study where inspection readiness and a validated audit trail are non negotiable, a biotech that wants its cro to run data management and benefits from the cro already having rave trained staff and templates, a sponsor standardising forms across a programme so that a global library is reused rather than each study being built from scratch, a device or phase iv study where rave lite gives the same compliance posture at a lower configuration burden. Of those, a sponsor running a registrational phase iii study where inspection readiness and a validated audit trail are non negotiable and a biotech that wants its cro to run data management and benefits from the cro already having rave trained staff and templates are not what Remesh is typically brought in for.
What can Medidata Rave do that Remesh cannot?
Medidata Rave covers Case report form design, Edit checks and queries, Part 11 audit trail, Rave Lite. Remesh covers Live moderated sessions, Collective dialogue, Flex asynchronous studies, Video research.

Answered from the vendors’ own pages

Medidata Rave: Who owns Medidata?

Dassault Systemes, which acquired Medidata in 2019. Rave is sold as part of the Dassault life sciences portfolio.

Remesh: How many people can join one session?

Sessions are designed for several hundred participants at once, which is the core reason to choose it over a conventional focus group.

Medidata Rave: How is Rave priced?

Per study, through a sales process. Nothing is published, and study build and amendments are charged separately from the licence.

Remesh: Does it publish pricing?

No. Contracts are quoted annually, typically scoped by session volume, and third-party estimates place them in the tens of thousands of dollars per year.

Medidata Rave: Is Rave validated out of the box?

Medidata supplies validation and qualification documentation, but the sponsor still owns study level user acceptance testing and its own validation evidence.

Remesh: Can it replace a survey?

Not entirely. It produces open-ended language with agreement percentages, which is stronger than a survey for understanding reasoning but weaker for precise population estimates.

Medidata Rave: What is Rave Lite for?

Lower complexity studies, typically Phase I, Phase IV and medical device, where a full study build is not justified.

Remesh: Does Remesh recruit participants for me?

Yes, through On-Demand Recruit, typically delivering a panel within about 24 hours, or you can bring your own list.

Share

Related pages

More on Medidata Rave

More on Remesh

Keep looking

Other head to heads